I69.292 Facial weakness following other nontraumatic intracranial hemorrhage

Name of the Condition

• Facial weakness following other nontraumatic intracranial hemorrhage
• ICD-10 Code: I69.292

Summary

This condition refers to facial weakness that develops as a long-term effect after a nontraumatic intracranial hemorrhage (bleeding within the skull not caused by injury). Facial weakness may involve impaired movement of the facial muscles, affecting expressions, speech, or eye closure, and can persist after the initial hemorrhage has resolved.

Causes

Facial weakness results from damage to brain regions controlling facial muscle function, typically caused by the initial nontraumatic intracranial hemorrhage. The hemorrhage may stem from a ruptured aneurysm, arteriovenous malformation, or spontaneous bleeding, leading to lasting impairments in facial motor control.

Risk Factors

• Hypertension (high blood pressure)
• Advanced age
• Smoking or excessive alcohol use
• Genetic predisposition to vascular disorders
• Use of anticoagulant medications
• Conditions like amyloid angiopathy or blood clotting disorders

Symptoms

• Asymmetry of facial features (e.g., drooping mouth or eyelid)
• Difficulty closing the eye on the affected side
• Impaired ability to smile, frown, or make other facial expressions
• Slurred speech or difficulty articulating sounds
• Reduced ability to eat or drink without spilling

Diagnosis

Clinical evaluation of facial weakness post-intracranial hemorrhage, including assessment of muscle strength, symmetry, and voluntary movement. Imaging studies (e.g., MRI or CT) may be used to identify residual brain damage or confirm the location of the initial hemorrhage. Electromyography (EMG) can assess nerve and muscle function.

Treatment Options

Treatment focuses on managing symptoms and supporting recovery. Physical therapy or speech therapy may help improve facial muscle control and function. In some cases, medications to address underlying conditions (e.g., blood pressure management) or assistive devices (e.g., eye patches) may be recommended. Surgical intervention is rarely indicated for isolated facial weakness.

Prognosis and Follow-Up

Prognosis varies depending on the extent of brain damage and the individual’s overall health. Some individuals may experience partial or full recovery over time, while others may have persistent weakness. Regular follow-up with a healthcare provider is important to monitor symptoms, adjust treatments, and address any new or worsening issues.

Complications

• Chronic facial asymmetry affecting appearance or function
• Eye irritation or injury due to inability to fully close the eye
• Difficulty with communication or social interactions
• Reduced quality of life due to persistent symptoms

Lifestyle & Prevention

• Manage hypertension and other vascular risk factors through diet, exercise, and medication as prescribed.
• Avoid smoking and limit alcohol use to reduce vascular strain.
• Follow up with healthcare providers to monitor and treat underlying conditions that increase hemorrhage risk.
• Use protective eyewear or lubrication if eye closure is impaired to prevent irritation.

When to Seek Professional Help

Seek immediate medical attention if facial weakness is sudden, severe, or accompanied by other neurological symptoms (e.g., headache, confusion, or weakness in other body parts), as these may indicate a new or worsening condition. Ongoing care is recommended for persistent weakness to optimize recovery and manage complications.

Tips for Medical Coders

This code (I69.292) is specific to facial weakness as a sequela of a nontraumatic intracranial hemorrhage. Documentation should clearly link the facial weakness to the prior hemorrhage and specify the nature of the impairment (e.g., unilateral or bilateral). Ensure the code is not used for facial weakness from other causes (e.g., trauma or infection) and that the underlying hemorrhage is appropriately coded.